It is being studied as a non-habit-forming option for patients dealing with disrupted sleep architecture, irregular schedules, or stress-related sleep issues
And the numbers were clear
In SURPASS-2, a head-to-head in T2D patients, tirzepatide 15 mg produced 11.2 kg weight loss versus 5.7 kg on semaglutide 1 mg (the T2D dose at the time, not the 2.4 mg obesity dose)
Final Verdict Kind Patches presents its product as a simpler alternative to GLP-1s, without medical involvement
When medication is reduced or stopped, appetite may return
does not offer any tools for tracking medication side effects or injection site rotation, leaving a gap for GLP-1 users